An Open-Label, Single-Arm, Dose Escalation and Expansion Phase 1 Study of Tebotelimab (MGD013) Plus Niraparib in Patients with Locally Advanced or Metastatic Gastric Cancer Who Failed Prior Treatments.
Journal of Clinical Oncology（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined